Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs First Trust NASDAQ Cybersecurity ETF (CIBR) Price & Performance

Bristol-Myers Squibb CoTrade
First Trust NASDAQ Cybersecurity ETFTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs First Trust NASDAQ Cybersecurity ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.81 (market cap $132.45B), while First Trust NASDAQ Cybersecurity ETF trades at $100.38. The key difference: Bristol-Myers Squibb Co pays a 3.89% dividend while First Trust NASDAQ Cybersecurity ETF pays none. Which is the better fit depends on your goals.

BMYCIBR
Market Cap
$132.45B
Sector
Health
52-Week High
$65.89$100.60
52-Week Low
$42.60$60.74
Enterprise Value
$166.44B
Dividend Yield
3.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $64.72, up 0.89% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a net income margin of 18.87% and ROE of 46.7%, though debt levels have risen. Recent news highlights a $2.3 billion manufacturing investment and merger speculation with AstraZeneca, driving investor interest.

BMY presents a mixed outlook: valuation metrics like P/E of 14.26 appear attractive, and analyst consensus targets $68.56. However, risks include patent expirations, high debt, and volatile cash flows. The stock's near-term performance hinges on merger developments and execution of growth initiatives amid competitive pressures.

First Trust NASDAQ Cybersecurity ETF

CIBR, the First Trust Nasdaq Cybersecurity ETF, trades at $97.85, up 1.51% on the day, with a bullish technical signal from moving averages. The ETF has shown strong performance, reportedly outperforming the S&P 500 by three to one year-to-date as of June 5, 2026 (24/7 Wall Street). Recent news highlights institutional activity, including Bank of America reducing its stake while First Trust Advisors increased its position.

The outlook for CIBR is positive, driven by growing cybersecurity spending exceeding $300 billion in 2026 and AI-driven demand. Risks include high concentration in tech stocks and market volatility. Analyst sentiment is optimistic, with upgrades citing reasonable valuations and secular growth trends.

Returns comparison

Trailing returns across standard periods

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About First Trust NASDAQ Cybersecurity ETF

The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index includes securities of companies classified as cyber security companies. The fund is non-diversified.

Read more on CIBR